Genentech expands RNAi pipeline
What happened
Genentech expanded its RNAi therapeutic pipeline through a global licensing deal with SanegeneBio, signaling confidence in next-gen therapeutic modalities.
Why it matters
The deal grants Genentech access to SanegeneBio's expertise in developing RNAi therapeutics for a range of disease targets. This collaboration highlights the growing interest in RNAi as a therapeutic approach, moving beyond traditional drug development methods. SanegeneBio will receive an upfront payment and is eligible for additional payments based on the achievement of certain milestones, as well as royalties on future sales. This financial structure allows SanegeneBio to benefit from the partnership while sharing the risk and reward with Genentech. Genentech's expansion into RNAi therapeutics reflects a strategic move to diversify its portfolio and capitalize on the potential of this innovative technology. RNAi therapies offer the possibility of targeting previously undruggable targets, potentially leading to treatments for a wider range of diseases.
What happens next
- The deal grants Genentech access to SanegeneBio's expertise in developing RNAi therapeutics for a range of disease targets.
- SanegeneBio will receive an upfront payment and is eligible for additional payments based on the achievement of certain milestones, as well as royalties on future sales.
- RNAi therapies offer the possibility of targeting previously undruggable targets, potentially leading to treatments for a wider range of diseases.
Sources
Quick answers
What happened in Genentech expands RNAi pipeline?
Genentech expanded its RNAi therapeutic pipeline through a global licensing deal with SanegeneBio, signaling confidence in next-gen therapeutic modalities.
Why does Genentech expands RNAi pipeline matter?
The deal grants Genentech access to SanegeneBio's expertise in developing RNAi therapeutics for a range of disease targets. This collaboration highlights the growing interest in RNAi as a therapeutic approach, moving beyond traditional drug development methods. SanegeneBio will receive an upfront payment and is eligible for additional payments based on the achievement of certain milestones, as well as royalties on future sales. This financial structure allows SanegeneBio to benefit from the partnership while sharing the risk and reward with Genentech. Genentech's expansion into RNAi therapeutics reflects a strategic move to diversify its portfolio and capitalize on the potential of this innovative technology. RNAi therapies offer the possibility of targeting previously undruggable targets, potentially leading to treatments for a wider range of diseases.
